How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies?
These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future.
Unfortunately, there aren’t solid answers at this point. But there are some people that can help!
Interview Highlights with Brian Contos
- Brian explains the following trends: From 2005-2011, lower extremity angioplasty procedures increased by 67%, venous ablations increased by 400%, and venous angioplasty 62%. Yet coronary intervention procedures decreased by 20%.
- How will the increased scrutiny regarding the appropriateness of certain procedures impact healthcare providers and medical device companies?
- The number of hospitals offering catheter-based revascularization has increased by 30% over last 10 years. What are the results of these trends?
- How will reduced reimbursement affect the recent influx of POL’s (physician-owned labs)?
- From 2008-2013, inpatient reimbursement of peripheral arterial revascularization increased by 15%. However, physician fee schedules for endovascular specialists have decreased substantially over the last 5 years. Will this continue?.
- Value-based purchasing (VBP) programs, readmissions reduction incentives, value-based payment modifiers for physicians, bundled payments for care improvement initiatives, and commercial ACOs. What do all of these healthcare delivery changes mean for medtech companies?
- Percutaneous transcatheter heart valves and renal denvervation. Is there too much hype around these two spaces? Brian provides us with his expert opinion.
- What is the one major initiative that medical device companies need to really grasp as we head into the new era of healthcare?
- And much more!
This Is What You Can Do Next
1) You can listen to the interview with Brian Contos right now:
2) You can also download the mp3 file of the interview by clicking here.
3) Read the following transcripts from my interview with Brian Contos.
Read the Interview with Brian Contos
More About Brian Contos
Brian Contos is the Executive Director for the Advisory Board Company, a global technology, research, and consulting firm partnering with 150,000 leaders in 3,700 organizations across healthcare and higher education.
Brian oversees the clinical research and insights programs. During his eleven years at the Advisory Board, he has researched and presented findings on topics that include service line finances, clinical quality, strategic planning, program operations, technology evaluation, and regulatory policy. Brian studied molecular and developmental biology at Yale University. His previous work includes infectious disease research at the Lippard Laboratory for Clinical Investigation at the Yale School of Medicine and cancer research at the Walt Disney Memorial Cancer Institute at Florida Hospital.